Aarti Pharmalabs Ltd Q4 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/t18yocjbpx9171zypic0srx7.pdf

Key Takeaways


CDMO/CMO: The Growth Engine

Hetal Gogri Gala: "Typically, all our customers are looking at us as a sustainable partner and to have a significant portfolio on their purchasing list, we find it, it is important for us to expand and be a world standard capacity for Xanthine business and that is a reason why we are expanding."

Xanthine: Price Bottom, Capacity Top-Up

Rashesh Gogri: "No, that manufacturing asset is operationally ready. But looking at the current manufacturing costs and the prices of product availability from China, we are not opting to continuously operate that plant, looking at very lower pricing availability from the market."

CAPEX Program: Building for FY26

Rashesh Gogri: "It's a very large land parcel that we have, we have close to 80 acre land and where we can do current expansion kind of 10 expansions. So, we can put 10 blocks of +100 crore CAPEX in the same site."

Margins & Profitability


R&D and New Capabilities

Piyush Lakhani: "the advantage that we are giving to our customers is completely non-dependence and also the green and sustainable manufacturing assets that we have, with the green power that we are now investing in and our overall total carbon footprint also much better than the other competitors."

Segment Performance

SegmentTrendCommentary
CDMO/CMO▲ Strong growthHighest contributor to incremental EBITDA; 21 commercial products, 19 under development; projecting 30–35% growth over 2–3 years.
API & Intermediates▲ ImprovingMost validations completed and DMS approved; better growth than the 10% seen last year is expected from this year onwards.
Xanthine▼ Price pressurePrices declined 20–25%, bottomed out; capacity utilization at 90%; expansion to 9,000 MT underway.

Guidance & Commitments

CommitmentSpecificsTimeline
EBITDA growthApproximately 10% to 12% growthFY25
Long-term annual growthAround 15%Next two years
CDMO/CMO growth30–35% growthNext 2–3 years
Gross marginClose to 50% on annual consolidated basisOngoing
Standalone EBITDA margin20% to 22%Ongoing
Atali greenfield commissioningPlant operationalQ4 FY25
Vapi semi-commercial blockOperational, revenue from Q2 FY25Q1 FY25
Solar power plantOperational, fulfilling 1/3 of power needsLast quarter FY25
Xanthine brownfield expansion5,000 to 9,000 MT capacity12–15 months to complete; FY27 for optimum utilization
New capacity sales contributionSales from new additional capacityFY26 onwards
High-barrier R&D segmentsPeptides, ADCs, sterile capabilities2–3 years to gain confidence

Key Metrics

MetricQ4 FY24
Consolidated EBITDA₹117.5 cr, +23% QoQ and +47% YoY
Consolidated PAT₹65.3 cr, +24% QoQ and +52% YoY
Standalone EBITDA₹107.3 cr, +22% QoQ and +40% YoY
Standalone PAT₹63 cr, +31% QoQ and +58% YoY
Consolidated EBITDA (full year FY24)₹386 cr, +13% YoY
Consolidated PAT (full year FY24)₹217 cr, +12% YoY, EPS ₹22.9
Standalone EBITDA (full year FY24)₹346.2 cr, +12% vs FY23
Standalone PAT (full year FY24)₹201 cr, +17% YoY, EPS ₹22.1
Return on capital employed (FY24)18%, up from 17.7% in FY23
Consolidated net debt to equity0.14% as on March 31, 2024
Standalone gross margin~55% in Q4
Consolidated gross margin~50% in Q4
EBITDA growth guidance for FY2510% to 12%
Long-term annual growth target~15% for the next two years
Standalone EBITDA margin guidance20% to 22%
Xanthine derivatives revenue share44% of Q4 turnover
API and Intermediates revenue share37.6% of Q4 turnover; regulated markets 54%, rest of world 34%, non-regulated 12%
CDMO/CMO revenue share18.4% of Q4 turnover
CDMO/CMO Q4 sales~₹76 cr, up from ~₹53 cr (per an analyst's math)
CDMO/CMO full year FY24 sales₹177 cr, up from ~₹100 cr in FY23
CDMO/CMO projects40 projects with 16 customers; 21 commercial, 19 under development
CDMO/CMO projects added in FY2412 new projects
Xanthine plant capacity utilization90%
Other plants capacity utilization85%
Xanthine capacity expansion target750 metric tonnes per month
Xanthine capacity debottleneckingFrom 5,000 to 9,000 metric tonnes
Xanthine price decline20% to 25% YoY
Xanthine volume growth12% to 15% YoY
Total CAPEX planned for FY25~₹600 cr
Atali greenfield project CAPEX~₹375 cr (apart from land cost of ₹50 cr)
Solar project CAPEX₹80-90 cr in FY25
Xanthine brownfield expansion CAPEX₹130-180 cr (still being finalized)
Intangible asset development spend (FY25)₹40-50 cr
R&D project write-off in Q4₹6.5 cr
Normalized tax rate25% to 25.5% of PBT
Final dividend recommended₹1 per share (in addition to interim dividend)